{"hands_on_practices": [{"introduction": "The journey of developing a new drug begins with measuring its potency and selectivity against its intended target. This practice simulates this foundational step, guiding you through the analysis of raw experimental data from an enzyme assay to determine the inhibitory constant ($K_i$) and isoform selectivity for an α-glucosidase inhibitor. By working from initial reaction progress curves to the final $K_i$ value [@problem_id:4996124], you will gain a hands-on understanding of how we quantify the very basis of a drug's pharmacological action.", "problem": "You are asked to design a computational workflow that emulates an in vitro kinetic assay panel to quantify selectivity across $\\alpha$-glucosidase isoforms and compute the inhibitory constant $K_i$ from provided progress curves. Use fundamental enzyme kinetics principles grounded in pharmacology, starting from the Michaelis-Menten framework and the definition of competitive inhibition. The inhibitor is a small molecule that competes with the substrate at the active site of the enzyme $\\alpha$-glucosidase; assume no other mechanisms such as mixed or noncompetitive inhibition are present. For each isoform, the substrate concentration $S$ is held fixed for all runs, and the canonical kinetic parameters $K_m$ and $V_{max}$ are known from prior characterization. A series of product formation progress curves $P(t)$ for different inhibitor concentrations $I$ is provided. Your task is to extract the initial velocities $v$ from the progress curves and, using principled derivations from the stated base, express $K_i$ in terms of quantities you can estimate. You must formulate and implement an algorithm that transforms the progress curves into $K_i$ estimates and then computes selectivity indices between isoforms.\n\nScientific base you must use:\n- Michaelis-Menten kinetics, which defines the catalytic transformation of substrate to product by an enzyme and the meaning of parameters $K_m$ and $V_{max}$.\n- Competitive inhibition, where the inhibitor binds the free enzyme, changing the apparent substrate affinity but not the maximal velocity, under a fixed substrate concentration $S$.\n- The initial velocity $v$ can be obtained from the slope of the early-time progress curve $P(t)$.\n\nYou must not use any unstated shortcut formulas. Derive your computational method from the above base in your solution. The method must be universally applicable to any modern programming language and must be implemented as a complete, runnable program in Python as specified. All concentrations must be treated and reported in micromolar (μM). Time must be treated in seconds (s). Initial velocities must be in μM/s. The final $K_i$ values must be expressed in μM, rounded to two decimal places. Selectivity indices must be computed as dimensionless ratios of $K_i$ values, rounded to two decimal places, and expressed as decimal numbers (not percentages).\n\nTest suite and data:\nFor three alpha-glucosidase isoforms, the fixed substrate concentration $S$, and the known parameters $K_m$ and $V_{max}$ are:\n- Isoform G1: $S = 200$ μM, $K_m = 300$ μM, $V_{max} = 1.8$ μM/s.\n- Isoform G2: $S = 200$ μM, $K_m = 150$ μM, $V_{max} = 1.2$ μM/s.\n- Isoform G3: $S = 200$ μM, $K_m = 500$ μM, $V_{max} = 2.0$ μM/s.\n\nFor each isoform, the inhibitor concentrations $I$ (in μM), the time points $t$ (in s), and the measured product concentrations $P(t)$ (in μM) are provided as follows. Each list of $P(t)$ corresponds to the same ordered list of time points $t = [0, 20, 40, 60]$ s.\n\nIsoform G1:\n- Inhibitor concentrations $I = [0, 20, 40, 80, 160]$ μM.\n- Progress curves $P(t)$ at each $I$:\n  - $I = 0$: [0, 14.4, 28.8, 43.2].\n  - $I = 20$: [0, 12.52173913, 25.04347826, 37.56521739].\n  - $I = 40$: [0, 11.07692308, 22.15384615, 33.23076923].\n  - $I = 80$: [0, 9.0, 18.0, 27.0].\n  - $I = 160$: [0, 6.545454545, 13.09090909, 19.63636364].\n\nIsoform G2:\n- Inhibitor concentrations $I = [0, 10, 20, 40, 80]$ μM.\n- Progress curves $P(t)$ at each $I$:\n  - $I = 0$: [0, 13.714285714285714, 27.428571428571427, 41.14285714285714].\n  - $I = 10$: [0, 11.294117647058824, 22.588235294117647, 33.88235294117647].\n  - $I = 20$: [0, 9.6, 19.2, 28.8].\n  - $I = 40$: [0, 7.384615384615385, 14.76923076923077, 22.153846153846153].\n  - $I = 80$: [0, 5.052631578947368, 10.105263157894736, 15.157894736842104].\n\nIsoform G3:\n- Inhibitor concentrations $I = [0, 50, 200, 1000]$ μM.\n- Progress curves $P(t)$ at each $I$:\n  - $I = 0$: [0, 11.428571428571429, 22.857142857142858, 34.285714285714285].\n  - $I = 50$: [0, 11.03448275862069, 22.06896551724138, 33.10344827586207].\n  - $I = 200$: [0, 10.0, 20.0, 30.0].\n  - $I = 1000$: [0, 6.666666666666667, 13.333333333333334, 20.0].\n\nTasks:\n1. For each isoform and inhibitor concentration $I$, estimate the initial velocity $v$ (in μM/s) from the corresponding progress curve $P(t)$ by fitting a straight line to $P$ versus $t$ over the provided time points and taking the slope. State and apply the rationale for using the initial slope as $v$.\n2. Using only the fundamental base above, derive an expression that connects $v$ and $I$ for competitive inhibition under fixed $S$, and identify a linearizable relationship that allows estimation of $K_i$ via least-squares fitting. Implement that estimation.\n3. Compute the $K_i$ (in μM) for each isoform G1, G2, and G3. Round each to two decimal places.\n4. Define the selectivity index $SI_{X/Y}$ between isoforms $X$ and $Y$ as the ratio $K_{i,X} / K_{i,Y}$ (dimensionless). Treat G1 as the reference (target) isoform and compute $SI_{\\text{G2}/\\text{G1}}$ and $SI_{\\text{G3}/\\text{G1}}$. Round each to two decimal places and express as decimal numbers without a percentage sign.\n5. Final output format: Your program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets, in the order [$K_{i,\\text{G1}}$, $K_{i,\\text{G2}}$, $K_{i,\\text{G3}}$, $SI_{\\text{G2}/\\text{G1}}$, $SI_{\\text{G3}/\\text{G1}}$], all rounded to two decimal places and with $K_i$ reported in μM.", "solution": "The computational design begins with the foundational description of enzyme catalysis and competitive inhibition. In Michaelis-Menten kinetics, the enzymatic transformation of substrate to product proceeds through the elementary steps $E + S \\rightleftharpoons ES \\rightarrow E + P$, and under steady-state assumptions the reaction velocity depends on the substrate concentration and the kinetic parameters. The key parameters are the Michaelis constant $K_m$ and the maximal velocity $V_{max}$. Competitive inhibition involves the inhibitor binding to the free enzyme to form $EI$, which reduces access of the substrate to the enzyme’s active site without changing the catalytic turnover at saturation, thereby affecting the apparent affinity for substrate. Under competitive inhibition at a fixed substrate concentration $S$, the initial velocity $v$ depends on both $S$ and the inhibitor concentration $I$ through the altered effective affinity.\n\nThe progress curve $P(t)$ represents the amount of product formed as a function of time $t$. In the early-time regime where $S$ does not appreciably deplete (a valid approximation in in vitro initial-rate assays and especially in the dataset provided where $P(t)$ increases linearly), the initial velocity $v$ is the slope of $P(t)$ with respect to $t$. Formally, in the short-time limit, $v = \\frac{dP}{dt}$. Operationally, we estimate $v$ by fitting a straight line to the measured $P(t)$ points and using the slope. Because each provided $P(t)$ is linear across the sampled times, ordinary least squares on the pairs $(t, P(t))$ yields an unbiased estimate of $v$ for each inhibitor concentration $I$.\n\nTo connect $v$ and $I$ for competitive inhibition under fixed $S$, begin with the principle that competitive inhibition modifies the effective substrate binding term while leaving $V_{max}$ unchanged. From the established Michaelis-Menten framework and the definition of competitive inhibition, one can derive that the dependence of $v$ on $I$ at fixed $S$ can be expressed in a form where the reciprocal of velocity $\\frac{1}{v}$ is an affine (linear) function of $I$. Specifically, introducing the constants $A = V_{max} \\cdot S$ and $B = K_m$, the relationship can be rearranged into\n$$\n\\frac{1}{v} = \\alpha + \\beta \\, I,\n$$\nwhere $\\alpha$ and $\\beta$ are constants that depend on $A$, $B$, and the inhibitory constant $K_i$. The constant $\\beta$ is directly proportional to $\\frac{B}{A}$ and inversely proportional to $K_i$, allowing $K_i$ to be recovered from the slope of the line fitted to the data pairs $(I, \\frac{1}{v})$. In particular, one can show that\n$$\n\\beta = \\frac{B}{A \\, K_i},\n$$\nwhich leads to the expression\n$$\nK_i = \\frac{B}{\\beta A} = \\frac{K_m}{\\beta \\, V_{max} \\, S}.\n$$\nThis linearization enables estimation of $K_i$ by a straightforward least-squares fit of $\\frac{1}{v}$ against $I$ to obtain $\\beta$, provided $K_m$, $V_{max}$, and $S$ are known and $v$ is estimated from the progress curves.\n\nAlgorithmic procedure:\n1. For each isoform and each inhibitor concentration $I$, compute the initial velocity $v$ by performing a least-squares linear regression of $P$ versus $t$ over the provided time points and taking the slope. Units: $v$ in μM/s since $P$ is in μM and $t$ in s.\n2. For each isoform, construct the data pairs $(I, \\frac{1}{v})$ using the $v$ values from step $1$. Perform a least-squares linear regression to fit $\\frac{1}{v} = \\alpha + \\beta I$, and extract the slope $\\beta$.\n3. Calculate $K_i$ for each isoform via $K_i = \\frac{K_m}{\\beta \\, V_{max} \\, S}$, with $K_i$ reported in μM. Round to two decimal places.\n4. Compute selectivity indices relative to G1: $SI_{\\text{G2}/\\text{G1}} = \\frac{K_{i,\\text{G2}}}{K_{i,\\text{G1}}}$ and $SI_{\\text{G3}/\\text{G1}} = \\frac{K_{i,\\text{G3}}}{K_{i,\\text{G1}}}$, rounded to two decimal places.\n5. Output the list [$K_{i,\\text{G1}}$, $K_{i,\\text{G2}}$, $K_{i,\\text{G3}}$, $SI_{\\text{G2}/\\text{G1}}$, $SI_{\\text{G3}/\\text{G1}}$] as a single line, with $K_i$ values in μM and selectivity indices as decimals.\n\nApplying the procedure to the provided data:\n- Isoform G1: $S = 200$ μM, $K_m = 300$ μM, $V_{max} = 1.8$ μM/s. The linear fits to $P(t)$ yield initial velocities approximately [0.72, 0.6260869565, 0.5538461538, 0.45, 0.3272727273] μM/s at $I = [0, 20, 40, 80, 160]$ μM. Fitting $\\frac{1}{v}$ versus $I$ gives a slope $\\beta$ near $0.0104166667$ $\\text{s/μM}^2$, yielding $K_i \\approx \\frac{300}{0.0104166667 \\cdot 1.8 \\cdot 200} \\approx 80$ μM.\n- Isoform G2: $S = 200$ μM, $K_m = 150$ μM, $V_{max} = 1.2$ μM/s. Initial velocities approximately [0.6857142857, 0.5647058824, 0.48, 0.3692307692, 0.2526315789] μM/s at $I = [0, 10, 20, 40, 80]$ μM. The fit gives $\\beta$ near $0.03125$ $\\text{s/μM}^2$, so $K_i \\approx \\frac{150}{0.03125 \\cdot 1.2 \\cdot 200} \\approx 20$ μM.\n- Isoform G3: $S = 200$ μM, $K_m = 500$ μM, $V_{max} = 2.0$ μM/s. Initial velocities approximately [0.5714285714, 0.5517241379, 0.5, 0.3333333333] μM/s at $I = [0, 50, 200, 1000]$ μM. The fit gives $\\beta$ near $0.00125$ $\\text{s/μM}^2$, yielding $K_i \\approx \\frac{500}{0.00125 \\cdot 2.0 \\cdot 200} \\approx 1000$ μM.\n\nSelectivity indices relative to G1:\n- $SI_{\\text{G2}/\\text{G1}} = \\frac{20}{80} = 0.25$.\n- $SI_{\\text{G3}/\\text{G1}} = \\frac{1000}{80} = 12.5$.\n\nRounded to two decimal places, the expected output is the single line with list [80.00, 20.00, 1000.00, 0.25, 12.50].", "answer": "```python\n# The complete and runnable Python 3 code goes here.\n# Imports must adhere to the specified execution environment.\nimport numpy as np\n\ndef estimate_initial_velocity(time_points, product_points):\n    \"\"\"\n    Estimate the initial velocity v (μM/s) by linear regression of P vs t.\n    Returns the slope of the best-fit line.\n    \"\"\"\n    # Fit P = m * t + b; m is the velocity.\n    m, b = np.polyfit(time_points, product_points, 1)\n    return m\n\ndef estimate_ki(S, Km, Vmax, inhibitor_concs, velocities):\n    \"\"\"\n    Estimate Ki using linearization: 1/v = alpha + beta * I,\n    where Ki = Km / (beta * Vmax * S).\n    \"\"\"\n    inv_v = 1.0 / np.array(velocities, dtype=float)\n    I = np.array(inhibitor_concs, dtype=float)\n    # Fit inv_v = alpha + beta * I\n    beta, alpha = np.polyfit(I, inv_v, 1)\n    Ki = Km / (beta * Vmax * S)\n    return Ki\n\ndef solve():\n    # Define the test cases from the problem statement.\n    # Each isoform includes S (μM), Km (μM), Vmax (μM/s),\n    # inhibitor concentrations (μM), time points (s), and progress curves P(t) (μM).\n    test_cases = [\n        {\n            \"name\": \"G1\",\n            \"S\": 200.0,\n            \"Km\": 300.0,\n            \"Vmax\": 1.8,\n            \"I_values\": [0.0, 20.0, 40.0, 80.0, 160.0],\n            \"time_points\": [0.0, 20.0, 40.0, 60.0],\n            \"P_values\": [\n                [0.0, 14.4, 28.8, 43.2],                      # I=0\n                [0.0, 12.52173913, 25.04347826, 37.56521739], # I=20\n                [0.0, 11.07692308, 22.15384615, 33.23076923], # I=40\n                [0.0, 9.0, 18.0, 27.0],                        # I=80\n                [0.0, 6.545454545, 13.09090909, 19.63636364], # I=160\n            ],\n        },\n        {\n            \"name\": \"G2\",\n            \"S\": 200.0,\n            \"Km\": 150.0,\n            \"Vmax\": 1.2,\n            \"I_values\": [0.0, 10.0, 20.0, 40.0, 80.0],\n            \"time_points\": [0.0, 20.0, 40.0, 60.0],\n            \"P_values\": [\n                [0.0, 13.714285714285714, 27.428571428571427, 41.14285714285714], # I=0\n                [0.0, 11.294117647058824, 22.588235294117647, 33.88235294117647], # I=10\n                [0.0, 9.6, 19.2, 28.8],                                            # I=20\n                [0.0, 7.384615384615385, 14.76923076923077, 22.153846153846153],  # I=40\n                [0.0, 5.052631578947368, 10.105263157894736, 15.157894736842104], # I=80\n            ],\n        },\n        {\n            \"name\": \"G3\",\n            \"S\": 200.0,\n            \"Km\": 500.0,\n            \"Vmax\": 2.0,\n            \"I_values\": [0.0, 50.0, 200.0, 1000.0],\n            \"time_points\": [0.0, 20.0, 40.0, 60.0],\n            \"P_values\": [\n                [0.0, 11.428571428571429, 22.857142857142858, 34.285714285714285], # I=0\n                [0.0, 11.03448275862069, 22.06896551724138, 33.10344827586207],    # I=50\n                [0.0, 10.0, 20.0, 30.0],                                            # I=200\n                [0.0, 6.666666666666667, 13.333333333333334, 20.0],                 # I=1000\n            ],\n        },\n    ]\n\n    # Compute Ki for each isoform.\n    ki_values = []\n    for case in test_cases:\n        S = case[\"S\"]\n        Km = case[\"Km\"]\n        Vmax = case[\"Vmax\"]\n        I_values = case[\"I_values\"]\n        time_points = np.array(case[\"time_points\"], dtype=float)\n\n        velocities = []\n        for P_curve in case[\"P_values\"]:\n            P = np.array(P_curve, dtype=float)\n            v = estimate_initial_velocity(time_points, P)\n            velocities.append(v)\n\n        Ki = estimate_ki(S, Km, Vmax, I_values, velocities)\n        ki_values.append(Ki)\n\n    # Compute selectivity indices relative to G1 (first isoform).\n    si_g2_over_g1 = ki_values[1] / ki_values[0]\n    si_g3_over_g1 = ki_values[2] / ki_values[0]\n\n    # Prepare results rounded to two decimals.\n    results = [\n        f\"{ki_values[0]:.2f}\",\n        f\"{ki_values[1]:.2f}\",\n        f\"{ki_values[2]:.2f}\",\n        f\"{si_g2_over_g1:.2f}\",\n        f\"{si_g3_over_g1:.2f}\",\n    ]\n\n    # Final print statement in the exact required format.\n    print(f\"[{','.join(results)}]\")\n\nsolve()\n```", "id": "4996124"}, {"introduction": "While the $K_i$ value provides a static measure of potency, a drug's true effect in the body is dynamic, as physiological conditions like substrate concentration are not constant. This exercise challenges you to model the efficacy of an α-glucosidase inhibitor over time following a meal, where the substrate concentration decays as it is digested. By calculating the time-averaged inhibition based on Michaelis-Menten kinetics [@problem_id:4996143], you will see how the principles of competitive inhibition play out in a more realistic, time-dependent context.", "problem": "A brush-border $\\alpha$-glucosidase in the proximal small intestine hydrolyzes meal-derived oligosaccharides to glucose. Consider a single-substrate enzyme under Michaelis–Menten steady-state kinetics in the intestinal lumen with a competitive $\\alpha$-glucosidase inhibitor co-administered at the start of a meal. Assume the following scientifically plausible scenario:\n\n- The intrinsic enzyme parameters are $V_{\\max} = 4.0$ mmol $\\text{min}^{-1}$ and $K_m = 5.0$ mM.\n- The inhibitor has a dissociation constant $K_i = 0.50$ mM, and its luminal concentration is constant at $[I] = 1.0$ mM during the observation window.\n- The meal-derived substrate concentration profile in the lumen is $[S](t) = S_0 \\exp(-k_s t)$ with $S_0 = 50$ mM and $k_s = 0.050$ $\\text{min}^{-1}$, for time $t$ in minutes post-ingestion.\n- The observation window is $t \\in [0, T]$ with $T = 60$ minutes.\n\nStarting from the definitions and laws of Michaelis–Menten steady-state kinetics and classical competitive inhibition (in which the inhibitor binds reversibly to the enzyme active site without altering $V_{\\max}$), do the following:\n\n1. Derive an expression for the instantaneous reaction velocity with inhibitor, $v_{\\text{with}}(t)$, and without inhibitor, $v_{\\text{without}}(t)$, as functions of $[S](t)$, $V_{\\max}$, $K_m$, $K_i$, and $[I]$.\n2. From your expressions, derive the fractional inhibition over time, $f(t)$, defined as $f(t) = 1 - \\dfrac{v_{\\text{with}}(t)}{v_{\\text{without}}(t)}$, and simplify it to depend only on $K_m$, $K_i$, $[I]$, and $[S](t)$.\n3. Compute the time-averaged fractional inhibition over the interval $[0, T]$, given by $\\dfrac{1}{T} \\int_{0}^{T} f(t)\\, dt$, using the parameter values above. Round your final numerical answer to four significant figures and express it as a unitless decimal (do not use the percent sign). If you report any intermediate reaction velocities, express them in mmol $\\text{min}^{-1}$.", "solution": "The problem statement has been critically evaluated and is determined to be valid. It is scientifically grounded in the principles of Michaelis–Menten enzyme kinetics and competitive inhibition, which are foundational concepts in biochemistry and pharmacology. The problem is well-posed, providing a complete and consistent set of parameters and definitions necessary to derive a unique, meaningful solution. The language is objective and unambiguous. We may therefore proceed with a formal solution.\n\nThe solution is structured in three parts as requested by the problem statement.\n\n1.  Derivation of expressions for the instantaneous reaction velocity with inhibitor, $v_{\\text{with}}(t)$, and without inhibitor, $v_{\\text{without}}(t)$.\n\nThe standard Michaelis–Menten equation describes the reaction velocity, $v$, as a function of the substrate concentration, $[S]$, the maximum velocity, $V_{\\max}$, and the Michaelis constant, $K_m$:\n$$v = \\frac{V_{\\max} [S]}{K_m + [S]}$$\nIn the absence of an inhibitor, the instantaneous reaction velocity, $v_{\\text{without}}(t)$, is obtained by substituting the time-dependent substrate concentration, $[S](t) = S_0 \\exp(-k_s t)$, into this equation.\n$$v_{\\text{without}}(t) = \\frac{V_{\\max} [S](t)}{K_m + [S](t)} = \\frac{V_{\\max} S_0 \\exp(-k_s t)}{K_m + S_0 \\exp(-k_s t)}$$\nThe problem describes a classical competitive inhibitor. In competitive inhibition, the inhibitor binds reversibly to the enzyme's active site, competing with the substrate. This process does not alter $V_{\\max}$ but increases the apparent Michaelis constant, $K_m$, to a new value, $K_{m,app}$. The relationship is given by:\n$$K_{m,app} = K_m \\left(1 + \\frac{[I]}{K_i}\\right)$$\nwhere $[I]$ is the inhibitor concentration and $K_i$ is the inhibitor dissociation constant.\n\nThe reaction velocity in the presence of the competitive inhibitor, $v_{\\text{with}}(t)$, is given by the Michaelis–Menten equation with $K_m$ replaced by $K_{m,app}$:\n$$v_{\\text{with}}(t) = \\frac{V_{\\max} [S](t)}{K_{m,app} + [S](t)} = \\frac{V_{\\max} [S](t)}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S](t)}$$\nSubstituting the expression for $[S](t)$:\n$$v_{\\text{with}}(t) = \\frac{V_{\\max} S_0 \\exp(-k_s t)}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + S_0 \\exp(-k_s t)}$$\n\n2.  Derivation of the fractional inhibition over time, $f(t)$.\n\nThe fractional inhibition, $f(t)$, is defined as $f(t) = 1 - \\frac{v_{\\text{with}}(t)}{v_{\\text{without}}(t)}$. We substitute the expressions derived in the first part:\n$$f(t) = 1 - \\frac{\\frac{V_{\\max} [S](t)}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S](t)}}{\\frac{V_{\\max} [S](t)}{K_m + [S](t)}}$$\nThe term $V_{\\max} [S](t)$ cancels, simplifying the ratio:\n$$\\frac{v_{\\text{with}}(t)}{v_{\\text{without}}(t)} = \\frac{K_m + [S](t)}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S](t)}$$\nSubstituting this back into the expression for $f(t)$:\n$$f(t) = 1 - \\frac{K_m + [S](t)}{K_m + \\frac{K_m [I]}{K_i} + [S](t)}$$\nTo combine the terms, we find a common denominator:\n$$f(t) = \\frac{\\left(K_m + \\frac{K_m [I]}{K_i} + [S](t)\\right) - \\left(K_m + [S](t)\\right)}{K_m + \\frac{K_m [I]}{K_i} + [S](t)}$$\nSimplifying the numerator:\n$$f(t) = \\frac{\\frac{K_m [I]}{K_i}}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + [S](t)}$$\nThis expression for $f(t)$ depends only on $K_m$, $K_i$, $[I]$, and $[S](t)$, as required.\n\n3.  Computation of the time-averaged fractional inhibition.\n\nThe time-averaged fractional inhibition, $\\langle f \\rangle$, over the interval $[0, T]$ is given by the integral:\n$$\\langle f \\rangle = \\frac{1}{T} \\int_{0}^{T} f(t) \\, dt$$\nSubstituting the derived expression for $f(t)$ and the given form of $[S](t)$:\n$$\\langle f \\rangle = \\frac{1}{T} \\int_{0}^{T} \\frac{\\frac{K_m [I]}{K_i}}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + S_0 \\exp(-k_s t)} \\, dt$$\nTo simplify the integral, let us define two constants. Let $A = \\frac{K_m [I]}{K_i}$ and $B = K_m \\left(1 + \\frac{[I]}{K_i}\\right)$. The integral becomes:\n$$\\langle f \\rangle = \\frac{1}{T} \\int_{0}^{T} \\frac{A}{B + S_0 \\exp(-k_s t)} \\, dt$$\nTo solve this integral, we multiply the numerator and denominator of the integrand by $\\exp(k_s t)$:\n$$\\langle f \\rangle = \\frac{A}{T} \\int_{0}^{T} \\frac{\\exp(k_s t)}{B \\exp(k_s t) + S_0} \\, dt$$\nWe perform a substitution. Let $u = B \\exp(k_s t) + S_0$. Then, the differential is $du = B k_s \\exp(k_s t) \\, dt$, which means $\\exp(k_s t) \\, dt = \\frac{du}{B k_s}$. The integral becomes:\n$$\\int \\frac{1}{u} \\frac{du}{B k_s} = \\frac{1}{B k_s} \\ln|u|$$\nSubstituting back for $u$ and applying the limits of integration from $t=0$ to $t=T$:\n\\begin{align*} \\langle f \\rangle &= \\frac{A}{T} \\left[ \\frac{1}{B k_s} \\ln\\left(B \\exp(k_s t) + S_0\\right) \\right]_{0}^{T} \\\\ &= \\frac{A}{T B k_s} \\left( \\ln\\left(B \\exp(k_s T) + S_0\\right) - \\ln\\left(B \\exp(0) + S_0\\right) \\right) \\\\ &= \\frac{A}{T B k_s} \\ln\\left( \\frac{B \\exp(k_s T) + S_0}{B + S_0} \\right) \\end{align*}\nSubstituting back the definitions of $A$ and $B$:\n$$\\langle f \\rangle = \\frac{\\frac{K_m [I]}{K_i}}{T \\cdot K_m \\left(1 + \\frac{[I]}{K_i}\\right) \\cdot k_s} \\ln\\left( \\frac{K_m \\left(1 + \\frac{[I]}{K_i}\\right) \\exp(k_s T) + S_0}{K_m \\left(1 + \\frac{[I]}{K_i}\\right) + S_0} \\right)$$\nNow, we substitute the provided numerical values:\n$K_m = 5.0$ mM\n$K_i = 0.50$ mM\n$[I] = 1.0$ mM\n$S_0 = 50$ mM\n$k_s = 0.050$ min$^{-1}$\n$T = 60$ min\n\nFirst, we compute the apparent Michaelis constant, which corresponds to our constant $B$:\n$$B = K_m \\left(1 + \\frac{[I]}{K_i}\\right) = 5.0 \\, \\text{mM} \\left(1 + \\frac{1.0 \\, \\text{mM}}{0.50 \\, \\text{mM}}\\right) = 5.0 \\, \\text{mM} (1 + 2) = 15.0 \\, \\text{mM}$$\nThe numerator of our expression for $f(t)$, our constant $A$, is:\n$$A = \\frac{K_m [I]}{K_i} = \\frac{5.0 \\, \\text{mM} \\cdot 1.0 \\, \\text{mM}}{0.50 \\, \\text{mM}} = 10.0 \\, \\text{mM}$$\nAlternatively, $A = B - K_m = 15.0 - 5.0 = 10.0$ mM.\n\nThe term in the exponent is $k_s T = 0.050 \\, \\text{min}^{-1} \\times 60 \\, \\text{min} = 3.0$.\nNow we substitute these values into the analytical solution for $\\langle f \\rangle$:\n$$\\langle f \\rangle = \\frac{10.0}{60 \\cdot 15.0 \\cdot 0.050} \\ln\\left( \\frac{15.0 \\cdot \\exp(3.0) + 50}{15.0 + 50} \\right)$$\nCalculating the pre-logarithmic factor:\n$$\\frac{10.0}{60 \\cdot 15.0 \\cdot 0.050} = \\frac{10.0}{60 \\cdot 0.75} = \\frac{10.0}{45.0} = \\frac{2}{9}$$\nCalculating the argument of the logarithm:\n$$\\frac{15.0 \\cdot \\exp(3.0) + 50}{65.0} \\approx \\frac{15.0 \\cdot (20.085537) + 50}{65.0} = \\frac{301.28305 + 50}{65.0} = \\frac{351.28305}{65.0} \\approx 5.404355$$\nNow we compute the final value:\n$$\\langle f \\rangle = \\frac{2}{9} \\ln(5.404355) \\approx \\frac{2}{9} \\cdot (1.687135) \\approx 0.3749189$$\nRounding to four significant figures, the time-averaged fractional inhibition is $0.3749$.", "answer": "$$\\boxed{0.3749}$$", "id": "4996143"}, {"introduction": "A drug's clinical success depends critically on its journey through the body, a field known as pharmacokinetics. This practice moves from the local enzyme-level effect to the whole-body perspective, highlighting how properties like systemic absorption and renal clearance dictate a drug's use in different patients. By calculating a necessary dose adjustment for a patient with renal impairment [@problem_id:4996161], you will apply core pharmacokinetic principles to make a rational, quantitative decision essential for safe and effective therapy.", "problem": "A clinician is choosing between two $\\alpha$-glucosidase inhibitors for a patient with type 2 diabetes mellitus and reduced renal function. One choice, miglitol, is known to be systemically absorbed from the small intestine and eliminated predominantly by the kidneys unchanged. The other choice, acarbose, has very low systemic absorption and acts primarily within the intestinal lumen, with minimal distribution beyond the gut and negligible renal elimination of parent drug. Using well-tested pharmacokinetic principles and definitions, first compare the absorption, distribution, and renal elimination of these two drugs, and then compute a renal dose adjustment for miglitol.\n\nAssume the following scientifically plausible and internally consistent data for miglitol in a typical adult with normal renal function:\n- Oral bioavailability $F_{\\text{miglitol}} = 0.95$.\n- Total body clearance under normal renal function $CL_{\\text{normal}} = 4.5 \\text{ L h}^{-1}$.\n- Fraction of total clearance that is renal under normal renal function $f_{r} = 0.90$.\n- Nonrenal clearance is the remainder.\n- Renal clearance scales linearly with creatinine clearance, defined as $CL_{r} \\propto \\text{Creatinine Clearance (CrCl)}$.\n- Reference normal creatinine clearance $\\text{CrCl}_{\\text{ref}} = 100 \\text{ mL min}^{-1}$.\n\nFor a $70 \\text{ kg}$ patient with measured $\\text{CrCl} = 30 \\text{ mL min}^{-1}$, the clinician wishes to maintain the same average steady-state exposure to miglitol (equivalently, the same area under the curve for a fixed dosing interval) as would be achieved in a patient with normal renal function receiving a maintenance dose of $100 \\text{ mg}$ three times daily (every $8$ $\\text{h}$). Use foundational pharmacokinetic relationships—linear kinetics, additivity of clearance components, and the dependence of steady-state exposure on the ratio of dose to clearance—to derive the appropriate per-dose adjustment for miglitol in this renally impaired patient, keeping the dosing interval unchanged.\n\nRound your final numerical answer to three significant figures. Express the adjusted per-dose maintenance amount in mg.", "solution": "The problem statement is evaluated as valid. It is scientifically grounded in established principles of pharmacology and pharmacokinetics, well-posed with all necessary and consistent data for a unique solution, and expressed in objective, formal language. The problem is a standard, non-trivial application of pharmacokinetic dose adjustment theory.\n\nThe problem requires a two-part response: first, a qualitative comparison of the pharmacokinetics of miglitol and acarbose, and second, a quantitative calculation of a dose adjustment for miglitol in a patient with renal impairment.\n\nFirst, we compare the pharmacokinetic properties of miglitol and acarbose based on the information provided.\n1.  **Absorption**: Miglitol is described as being systemically absorbed from the small intestine with an oral bioavailability ($F$) of $0.95$. This indicates that $95\\%$ of the orally administered dose reaches the systemic circulation to exert its effects and be subject to systemic clearance. In contrast, acarbose has very low systemic absorption, meaning it largely remains within the gastrointestinal (GI) tract, its site of action, with a negligible amount entering the bloodstream.\n2.  **Distribution**: Following its high systemic absorption, miglitol distributes throughout the body via the bloodstream. Acarbose, due to its minimal absorption, has a distribution that is primarily limited to the intestinal lumen.\n3.  **Elimination**: Miglitol is eliminated predominantly by the kidneys as an unchanged drug. The fraction of total clearance that is renal ($f_r$) is given as $0.90$. This high dependence on renal function for elimination makes its exposure sensitive to changes in kidney function. Acarbose, with its negligible systemic absorption, consequently has negligible renal elimination of the parent drug, as very little of it ever reaches the kidneys.\n\nDue to these profound differences, a patient with reduced renal function would be at high risk of drug accumulation and potential toxicity with a standard dose of miglitol, as its primary elimination pathway is impaired. Acarbose would not pose a similar risk related to renal impairment, making it a safer choice in this specific context without dose adjustment.\n\nNext, we proceed with the quantitative dose adjustment for miglitol. The clinical objective is to maintain the same average steady-state drug exposure in the renally impaired patient as in a patient with normal renal function. In linear pharmacokinetics, the average steady-state exposure is represented by the area under the plasma concentration-time curve over one dosing interval ($\\tau$), denoted $AUC_{\\tau,ss}$. This is given by the formula:\n$$ AUC_{\\tau,ss} = \\frac{F \\cdot Dose}{CL} $$\nwhere $F$ is the oral bioavailability, $Dose$ is the dose administered per interval $\\tau$, and $CL$ is the total body clearance.\n\nTo maintain the same exposure ($AUC_{\\tau,ss, \\text{patient}} = AUC_{\\tau,ss, \\text{normal}}$) with an unchanged dosing interval and drug formulation ($F$ is constant), the following relationship must hold:\n$$ \\frac{F \\cdot Dose_{\\text{patient}}}{CL_{\\text{patient}}} = \\frac{F \\cdot Dose_{\\text{normal}}}{CL_{\\text{normal}}} $$\nThe bioavailability $F$ cancels, leading to the dose adjustment formula:\n$$ Dose_{\\text{patient}} = Dose_{\\text{normal}} \\cdot \\frac{CL_{\\text{patient}}}{CL_{\\text{normal}}} $$\nOur task reduces to calculating the total clearance in the patient, $CL_{\\text{patient}}$.\n\nTotal body clearance ($CL$) is the sum of renal clearance ($CL_r$) and non-renal clearance ($CL_{nr}$):\n$$ CL = CL_r + CL_{nr} $$\n\nWe first determine the clearance components for a person with normal renal function.\nGiven:\n- Total clearance in normal function, $CL_{\\text{normal}} = 4.5 \\text{ L h}^{-1}$.\n- Fraction of renal clearance, $f_r = 0.90$.\n- Normal dose, $Dose_{\\text{normal}} = 100 \\text{ mg}$.\n\nThe renal clearance in a person with normal function is:\n$$ CL_{r, \\text{normal}} = f_r \\cdot CL_{\\text{normal}} = 0.90 \\cdot 4.5 \\text{ L h}^{-1} = 4.05 \\text{ L h}^{-1} $$\nThe non-renal clearance is the remainder:\n$$ CL_{nr} = CL_{\\text{normal}} - CL_{r, \\text{normal}} = 4.5 \\text{ L h}^{-1} - 4.05 \\text{ L h}^{-1} = 0.45 \\text{ L h}^{-1} $$\nNon-renal clearance is assumed to be unaffected by changes in kidney function.\n\nNow, we calculate the clearance components for the patient with renal impairment.\nGiven:\n- Patient's creatinine clearance, $\\text{CrCl}_{\\text{patient}} = 30 \\text{ mL min}^{-1}$.\n- Reference normal creatinine clearance, $\\text{CrCl}_{\\text{ref}} = 100 \\text{ mL min}^{-1}$.\n\nThe problem states that miglitol's renal clearance ($CL_r$) is directly proportional to creatinine clearance ($\\text{CrCl}$). Therefore, we can find the patient's renal clearance by scaling the normal renal clearance by the ratio of the patient's $\\text{CrCl}$ to the reference $\\text{CrCl}$:\n$$ CL_{r, \\text{patient}} = CL_{r, \\text{normal}} \\cdot \\frac{\\text{CrCl}_{\\text{patient}}}{\\text{CrCl}_{\\text{ref}}} $$\n$$ CL_{r, \\text{patient}} = 4.05 \\text{ L h}^{-1} \\cdot \\frac{30 \\text{ mL min}^{-1}}{100 \\text{ mL min}^{-1}} = 4.05 \\text{ L h}^{-1} \\cdot 0.3 = 1.215 \\text{ L h}^{-1} $$\nThe total clearance in the patient is the sum of their impaired renal clearance and their unchanged non-renal clearance:\n$$ CL_{\\text{patient}} = CL_{r, \\text{patient}} + CL_{nr} = 1.215 \\text{ L h}^{-1} + 0.45 \\text{ L h}^{-1} = 1.665 \\text{ L h}^{-1} $$\n\nFinally, we calculate the adjusted dose for the patient:\n$$ Dose_{\\text{patient}} = Dose_{\\text{normal}} \\cdot \\frac{CL_{\\text{patient}}}{CL_{\\text{normal}}} $$\n$$ Dose_{\\text{patient}} = 100 \\text{ mg} \\cdot \\frac{1.665 \\text{ L h}^{-1}}{4.5 \\text{ L h}^{-1}} $$\n$$ Dose_{\\text{patient}} = 100 \\text{ mg} \\cdot 0.37 = 37 \\text{ mg} $$\nThe problem requires the final answer to be rounded to three significant figures.\n$$ Dose_{\\text{patient}} = 37.0 \\text{ mg} $$\nThus, the adjusted per-dose maintenance amount for miglitol in this patient is $37.0$ $\\text{mg}$, administered three times daily.", "answer": "$$\n\\boxed{37.0}\n$$", "id": "4996161"}]}